ArticleVaccines2025

A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults.

Angela Branche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.